For research use only. Not for therapeutic Use.
(S)-Ceralasertib（Cat No.:I018275）, also known as AZD6738, is a potent and selective inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a key enzyme involved in the DNA damage response. By inhibiting ATR, (S)-Ceralasertib impairs the ability of cancer cells to repair DNA damage, particularly in tumors with existing defects in DNA repair mechanisms, such as BRCA mutations. This leads to increased genomic instability and apoptosis in cancer cells. (S)-Ceralasertib has shown promise in preclinical and clinical studies, especially in combination with other treatments like chemotherapy and immunotherapy, for cancers like ovarian and lung cancer.
| Catalog Number | I018275 |
| CAS Number | 1352226-87-9 |
| Molecular Formula | C₂₀H₂₄N₆O₂S |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane |
| InChI | InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29+/m1/s1 |
| InChIKey | OHUHVTCQTUDPIJ-MUWSIPGASA-N |
| SMILES | C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@@](=N)(=O)C)C4=C5C=CNC5=NC=C4 |
| Reference | [1]. By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215.<br>[2]. Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907. |
